Third, the Shc3-mediated β-catenin/TCF pathway can induce the activation of MDR1 and stemness-associated transcription factors, thus promoting HCC stemness and reducing sensitivity to sorafenib and doxorubicin. This evidence concerns the gene SHC3 and hepatocellular carcinoma.